In conjunction with our drug sensitivity and molecular characterization data, our 3D assays, done by using our proprietary patient-derived xenograft (PDX) explants, enable you to evaluate the potency of your compound compared to standard-of-care drugs. This allows you to identify the most promising drug candidates, tumor histotypes and molecular subtypes for further testing.

Data collected in these assays can then be used to select PDX models for subsequent in vivo efficacy tests. The data can also be used to run systematic two-drug combination therapy studies over a range of concentrations and to correlate the tumor response with molecular data (biomarker identification).

You may also be interested in...

Cancer cell

Feature Story

As head of the Tumor Biology Modeling Lab, Julia Schüler, PhD, DVM, brings a breadth of experience and a plan to improve clinical success rates of our clients’ oncology discovery programs.

Webinar Replay

View our recent webinar on cost- and time-effective methods of determining the most appropriate in vivo models for your oncology preclinical program.

Syngeneic Models

Charles River offers syngeneic mouse models suitable for the evaluation of immunobiological-based therapies.

Logo screenshot

Charles River’s Entire Discovery Portfolio

Charles River offers the most comprehensive drug discovery service portfolio in the industry, supported by scientific excellence across major therapeutic areas and target classes.